Abeona Therapeutics - ABEO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 403.31%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.55
▼ -0.24 (-3.08%)

This chart shows the closing price for ABEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abeona Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABEO

Analyst Price Target is $38.00
▲ +403.31% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Abeona Therapeutics in the last 3 months. The average price target is $38.00, with a high forecast of $38.00 and a low forecast of $38.00. The average price target represents a 403.31% upside from the last price of $7.55.

This chart shows the closing price for ABEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Abeona Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/24/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$38.00Low
11/8/2022Cantor FitzgeraldBoost TargetOverweight$22.00 ➝ $40.00Low
9/15/2022Alliance Global PartnersInitiated CoverageBuyLow
8/11/2022Cantor FitzgeraldBoost Target$15.00 ➝ $22.00Low
11/30/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$125.00 ➝ $25.00Medium
11/29/2021HC WainwrightLower TargetBuy$125.00 ➝ $100.00High
11/18/2021Cantor FitzgeraldReiterated RatingOverweightHigh
10/6/2021HC WainwrightReiterated RatingBuy$125.00High
7/19/2021HC WainwrightLower TargetBuy$200.00 ➝ $125.00High
4/14/2021HC WainwrightReiterated RatingBuy$200.00High
3/29/2021SVB LeerinkReiterated RatingBuyLow
2/16/2021SVB LeerinkReiterated RatingOutperformLow
2/16/2021HC WainwrightReiterated RatingBuy$200.00Low
11/25/2020HC WainwrightLower TargetBuy$275.00 ➝ $200.00Low
11/11/2020B. RileyReiterated RatingBuy$50.00 ➝ $75.00High
11/10/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$100.00High
11/10/2020SVB LeerinkLower TargetOutperform$200.00 ➝ $125.00Low
10/6/2020B. RileyReiterated RatingBuy$50.00Low
9/18/2020B. RileyInitiated CoverageBuy$125.00 ➝ $125.00High
7/13/2020HC WainwrightReiterated RatingBuy$275.00High
5/8/2020Royal Bank of CanadaLower TargetOutperform$275.00 ➝ $175.00High
5/7/2020MizuhoReiterated RatingHold$100.00High
4/2/2020HC WainwrightReiterated RatingBuyLow
3/18/2020Royal Bank of CanadaLower TargetOutperform$350.00 ➝ $275.00High
1/21/2020HC WainwrightInitiated CoverageBuy$275.00High
12/30/2019HC WainwrightReiterated RatingBuy$375.00 ➝ $275.00Low
12/11/2019HC WainwrightReiterated RatingBuy$375.00Low
12/10/2019Cantor FitzgeraldInitiated CoverageHold$100.00High
12/10/2019MizuhoReiterated RatingHold$100.00High
11/20/2019HC WainwrightReiterated RatingBuy$375.00Medium
11/14/2019MizuhoReiterated RatingHold$100.00Medium
10/18/2019Cantor FitzgeraldReiterated RatingNeutralMedium
10/16/2019HC WainwrightReiterated RatingBuy$375.00High
9/23/2019MizuhoReiterated RatingHold$100.00Medium
9/4/2019MizuhoReiterated RatingHold$100.00High
8/15/2019Maxim GroupDowngradeBuy ➝ HoldHigh
8/13/2019Royal Bank of CanadaLower TargetOutperform ➝ Positive$400.00High
8/12/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
8/12/2019HC WainwrightInitiated CoverageBuy$375.00High
7/26/2019MizuhoDowngradeBuy ➝ Neutral$425.00 ➝ $100.00High
6/26/2019MizuhoInitiated CoverageBuy ➝ BuyHigh
5/28/2019HC WainwrightSet TargetBuy$575.00Low
5/14/2019Cantor FitzgeraldReiterated RatingBuy$725.00Medium
5/6/2019HC WainwrightReiterated RatingBuyHigh
5/1/2019Maxim GroupReiterated RatingBuyLow
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/17/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/14/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Abeona Therapeutics logo
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Read More

Today's Range

Now: $7.55
Low: $7.43
High: $7.84

50 Day Range

MA: $7.20
Low: $4.29
High: $8.68

52 Week Range

Now: $7.55
Low: $2.73
High: $9.01

Volume

188,039 shs

Average Volume

302,436 shs

Market Capitalization

$206.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Abeona Therapeutics?

The following Wall Street research analysts have issued reports on Abeona Therapeutics in the last twelve months: Cantor Fitzgerald, and StockNews.com.
View the latest analyst ratings for ABEO.

What is the current price target for Abeona Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Abeona Therapeutics in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 403.3%. Cantor Fitzgerald has the highest price target set, predicting ABEO will reach $38.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $38.00 for Abeona Therapeutics in the next year.
View the latest price targets for ABEO.

What is the current consensus analyst rating for Abeona Therapeutics?

Abeona Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABEO will outperform the market and that investors should add to their positions of Abeona Therapeutics.
View the latest ratings for ABEO.

What other companies compete with Abeona Therapeutics?

How do I contact Abeona Therapeutics' investor relations team?

Abeona Therapeutics' physical mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company's listed phone number is 214-665-9495 and its investor relations email address is [email protected]. The official website for Abeona Therapeutics is www.abeonatherapeutics.com. Learn More about contacing Abeona Therapeutics investor relations.